Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZG005 plus paclitaxel and platinum with or without bevacizumab in advanced cervical cancer
CTR20234267Phase 2Active
- Sponsor
- Zelgen
- Start
- Mar 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig in Cervical Cancer (CC), sponsored by Zelgen. Started Mar 2024; status: active.
02
Drugs
nilvanstomig
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20234267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234267.